Plasma Protease C1- Inhibitor Treatment Market By Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist); By Dosage (Lyophilized, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Prospective Landscape, Size, Share, Growth, Opportunities and Industry Forecast 2020-2028

Published DateReport CodeNo. of PagesReport Format
November– 2020AMR-9079110PDF / Excel
  • The global Plasma Protease C1- Inhibitor Treatment market size is accounted to grow from US$ 3290 million in 2020 and projected to reach US$ 12535.33 million at a CAGR of 18.2 % over the forecast period.

SelectLicense Type

Market Insights:

C1-inhibitor (C1-INH, C1 esterase inhibitor) is a protease inhibitor having a place with the serpin superfamily. Its fundamental capacity is the inhibition of the complement system to forestall unconstrained enactment yet in addition as the significant controller of the contact system. The Plasma Protease C1-inhibitor Treatment Market is required to encounter a critical development over the estimated time frame because of the developing frequency of hereditary angioedema  (HAE). hereditary angioedema is a conceivably dangerous hereditary condition with a rate between 1 out of 10,000 and 1 of every 50,000 individuals as indicated by HAE International (HAEi), the worldwide umbrella association for the world’s HAE patient groups. Hereditary angioedema (HAE) is an autosomal problem described by low degrees of utilitarian C1 esterase inhibitor protein. Filtered concentrate of C1 esterase inhibitors are utilized in HAE influenced patients for the prophylactic and intense assault therapy of HAE. A few plasma protease C1-inhibitors, for example, Firazyr, Cinryze, Kalbitor, and Berinet have been affirmed for the prophylactic and intense assault therapy of hereditary angioedema.

Latest Trends:

The following are the trending factors encouraging the Plasma protease C1-Inhibitor treatment market growth over the coming years:

  • Growing incidence of hereditary angioedema (HAE).
  • Biopharmaceutical companies focusing on the development of effective plasma protease C1-inhibitor.
  • Adoption of inorganic development techniques.
  • Selective Bradykinin B2 Receptor Antagonist Segment is expected to increase the market.
  • Increased product approvals.

Driving Factors:

  • Factors such as the revelation of inhibitor drugs, expanding R&D investments, expanding item endorsements promising pipeline medications, and novel treatments for the treatment of hereditary angioedema are a couple of different elements driving the plasma protease c1 inhibitor treatment market.
  • Hereditary angioedema is a conceivably hazardous hereditary condition. Incidences of hereditary angioedema (HAE) increasing day by day. The growing incidence of hereditary angioedema (HAE) is the major factor in boosting the protease c1 inhibitor treatment market.
  • Biopharmaceutical companies focusing on developing effective plasma protease C1-inhibitor treatment drugs/therapies for treating various health conditions such as diabetic macular edema (DME), HAE, and others, are propelling the plasma protease C1-inhibitor treatment market.
  • Adoption of inorganic development techniques, for example, organizations and coordinated efforts, to create innovative protease C1-inhibitor treatment is fundamentally adding to the development of the global plasma protease C1-inhibitor treatment market.

Restraining Factors:

  • The less occurrence of the HAE makes it hard for the productive conclusion and picking alternative treatments to control the infection is the central point that is relied upon to limit the plasma protease c1-inhibitor treatment market development.
  • The spread of the novel coronavirus has hampered the growth of the healthcare industry and the virus has spread rapidly across the globe. Various research institutes and biopharmaceutical companies are engaged in the study of the effects of plasma protease C1-inhibitors in treating significant systemic abnormalities in patients with COVID‐ This factor hampers the growth of the C1-inhibitors market.

Segmentations:

The global Plasma protease C1-Inhibitor treatment market has been bifurcated into different global market segments by examining various perspectives such as drug type, dosage, distribution channel, and global geographies. Based on drug type, it can be divided into C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist. Based on dosage, it can be divided into Lyophilized and Injectable. Based on the distribution channel, it can be divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Drug Type Perspective (Revenue in US$ Million):

  • C1-inhibitors
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist

Dosage Perspective (Revenue in US$ Million):

  • Lyophilized
  • Injectable

Distribution Channel Perspective (Revenue in US$ Million):

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Perspective (Revenue in US$ Million):

North America

  • U.S.A
  • Canada

Europe

  • Italy
  • Germany
  • France
  • UK
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico

Middle East & Africa

  • UAE
  • Saudi Arabia
  • Turkey
  • Rest of Middle East & Africa

Regional Insights:

  • The global Plasma protease C1-Inhibitor treatment market has been scrutinized into different global market regions such as North America, Asia-Pacific, Africa, and Europe, Latin America, and the Middle East based on different global market segments.
  • North American plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, inferable from expanding endorsements of novel treatments by the administrative offices, for example, the U.S. Food and Drug Administration. For example, in 2014, the U.S. FDA affirmed Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.
  • In North America, rising Hereditary Angioedema (HAE) and expanding R&D ventures. Different factors additionally incorporate the presence of entrenched medical care framework, an expanding number of item endorsements, and significant market players giving successful therapy choices to the patients experiencing Hereditary Angioedema in North America. These factors increase the demand for the Plasma Protease C1-inhibitor market.

Key Industry Players:

Different global established global companies in the global Plasma protease C1-Inhibitor treatment market have been examined with the help of research methodologies for getting effective insights based on various perspectives. Furthermore, different factors such as collaborations, mergers, and acquisitions, partnerships of leading competitors have been presented in the report. Furthermore, a different financial factor such as financial overview, profit margin, revenue generation, and investments have been estimated by an expert team of Alchemy Market Research.

The following leading companies have been profiled to get detailed insights into leading companies in the Plasma protease C1-Inhibitor treatment market:

  • CSL Behring LLC
  • Takeda Pharmaceutical Company Limited
  • BioCryst Pharmaceuticals
  • Pharming Technologies B.V
  • Centogene AG
  • KalVista Pharmaceuticals, Inc
  • Ionis Pharmaceuticals, Inc

Key Industry Developments:

  • In October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 for the development of potential treatment of diabetic macular edema (DME).

This report answers the following key questions:

  • What is the global Plasma protease C1-Inhibitor treatment market?
  • Which factors are encouraging and driving the global Plasma protease C1-Inhibitor treatment market?
  • What are the upcoming trends and evolution of the Plasma protease C1-Inhibitor treatment market?
  • What are the challenges, threats, and issues faced by the global Plasma protease C1-Inhibitor treatment market?
  • What will be the global market size and market shares over the forecast period?
  • What are the global leading key players functioning in the global Plasma protease C1-Inhibitor treatment market?
  • What are the outcomes of SWOT and Porter’s five forces analysis?
  • What are the technological advancements and trends in the global Plasma protease C1-Inhibitor treatment market?
  • What is the impact of the Covid-19 viral outbreak on the global Plasma protease C1-Inhibitor treatment market?
  • What will be the global Plasma protease C1-Inhibitor treatment market growth opportunities over the forecast period?
  • Which are the major segments accounted for registering the largest share in the global Plasma protease C1-Inhibitor treatment market?

Synopsis:

Alchemy Market Research has newly published a fully-fledged analysis on the global Plasma protease C1-Inhibitor treatment market to its large volume of database. The global Plasma protease C1-Inhibitor treatment market size is accounted to hold at US$ 3290 million in 2020 and is projected to register a CAGR of 18.2 % over the forecast period. The global market data has been collected through a blend of research techniques such as primary and secondary research. Furthermore, an expert team of Alchemy Market Research makes use of qualitative and quantitative analysis. The business intelligence report highlights the recent updates of the global market along with its statistics for a better understanding of the present scenario of the market.

Chapter 1.        Executive Summary

 

Chapter 2.        Market Introduction

 

Chapter 3.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics

3.1.   Key Market Drivers

3.2.   Key Market Restraints

3.3.   Market Opportunities

3.4.   Future Trends

3.5.   Impact Analysis of Drivers and Restraints

Chapter 4.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

 

Chapter 5.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Drug Type

5.1.   C1-inhibitors

5.2.   Kallikrein Inhibitor

5.3.   Selective Bradykinin B2 Receptor Antagonist

Chapter 6.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Dosage

6.1.   Lyophilized

6.2.   Injectable

Chapter 7.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Distribution Channel

7.1.   Hospital Pharmacies

7.2.   Retail Pharmacies

7.3.   Online Pharmacies

Chapter 8.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Region

8.1.   North America

8.2.   Europe

8.3.   Asia-Pacific

8.4.   Latin America

8.5.   Middle East & Africa

Chapter 9.        North America Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

9.1.   North America Plasma Protease C1- inhibitor treatment Market– By Drug Type

9.1.1.C1-inhibitors

9.1.2.Kallikrein Inhibitor

9.1.3.Selective Bradykinin B2 Receptor Antagonist

9.2.   North America Plasma Protease C1- inhibitor treatment Market– By Dosage

9.2.1.Lyophilized

9.2.2.Injectable

9.3.   North America Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

9.3.1.Hospital Pharmacies

9.3.2.Retail Pharmacies

9.3.3.Online Pharmacies

9.4.   North America Plasma Protease C1- inhibitor treatment Market– By Country

9.4.1.U.S.

9.4.2.Canada

Chapter 10.    Europe Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

10.1.            Europe Plasma Protease C1- inhibitor treatment Market– By Drug Type

10.1.1.    C1-inhibitors

10.1.2.    Kallikrein Inhibitor

10.1.3.    Selective Bradykinin B2 Receptor Antagonist

10.2.            Europe Plasma Protease C1- inhibitor treatment Market– By Dosage

10.2.1.    Lyophilized

10.2.2.    Injectable

10.3.            Europe Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

10.3.1.    Hospital Pharmacies

10.3.2.    Retail Pharmacies

10.3.3.    Online Pharmacies

10.4.            Europe Plasma Protease C1- inhibitor treatment Market– By Country

10.4.1.    Germany

10.4.2.    France

10.4.3.    UK

10.4.4.    Spain

10.4.5.    Italy

10.4.6.    Rest of Europe

Chapter 11.    Asia Pacific Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

11.1.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Drug Type

11.1.1.    C1-inhibitors

11.1.2.    Kallikrein Inhibitor

11.1.3.    Selective Bradykinin B2 Receptor Antagonist

11.2.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Dosage

11.2.1.    Lyophilized

11.2.2.    Injectable

11.3.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

11.3.1.    Hospital Pharmacies

11.3.2.    Retail Pharmacies

11.3.3.    Online Pharmacies

11.4.            Asia-Pacific Plasma Protease C1- inhibitor treatment Market– By Country

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. South Korea

11.4.5. Rest of Asia-Pacific

Chapter 12.    Latin America Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

12.1.            Latin America Plasma Protease C1- inhibitor treatment Market– By Drug Type

12.1.1.    C1-inhibitors

12.1.2.    Kallikrein Inhibitor

12.1.3.    Selective Bradykinin B2 Receptor Antagonist

12.2.            Latin America Plasma Protease C1- inhibitor treatment Market– By Dosage

12.2.1.    Lyophilized

12.2.2.    Injectable

12.3.            Latin America Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

12.3.1.    Hospital Pharmacies

12.3.2.    Retail Pharmacies

12.3.3.    Online Pharmacies

12.4.            Latin America Plasma Protease C1- inhibitor treatment Market– By Country

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

Chapter 13.    Middle East & Africa Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

13.1.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Drug Type

13.1.1.    C1-inhibitors

13.1.2.    Kallikrein Inhibitor

13.1.3.    Selective Bradykinin B2 Receptor Antagonist

13.2.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Dosage

13.2.1.    Lyophilized

13.2.2.    Injectable

13.3.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

13.3.1.    Hospital Pharmacies

13.3.2.    Retail Pharmacies

13.3.3.    Online Pharmacies

13.4.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Country

13.4.1. UAE

13.4.2. Saudi Arabia

13.4.3. Turkey

13.4.4. Rest of Middle East & Africa

Chapter 14.    Competitive Analysis

14.1.1. Competition Dashboard

14.1.2. Company Profiles

14.1.2.1.          CSL Behring LLC

14.1.2.2.          Takeda Pharmaceutical Company Limited

14.1.2.3.          BioCryst Pharmaceuticals

14.1.2.4.          Pharming Technologies B.V

14.1.2.5.          Centogene AG

14.1.2.6.          KalVista Pharmaceuticals, Inc

Ionis Pharmaceuticals, Inc

Report Description

Market Insights:

C1-inhibitor (C1-INH, C1 esterase inhibitor) is a protease inhibitor having a place with the serpin superfamily. Its fundamental capacity is the inhibition of the complement system to forestall unconstrained enactment yet in addition as the significant controller of the contact system. The Plasma Protease C1-inhibitor Treatment Market is required to encounter a critical development over the estimated time frame because of the developing frequency of hereditary angioedema  (HAE). hereditary angioedema is a conceivably dangerous hereditary condition with a rate between 1 out of 10,000 and 1 of every 50,000 individuals as indicated by HAE International (HAEi), the worldwide umbrella association for the world’s HAE patient groups. Hereditary angioedema (HAE) is an autosomal problem described by low degrees of utilitarian C1 esterase inhibitor protein. Filtered concentrate of C1 esterase inhibitors are utilized in HAE influenced patients for the prophylactic and intense assault therapy of HAE. A few plasma protease C1-inhibitors, for example, Firazyr, Cinryze, Kalbitor, and Berinet have been affirmed for the prophylactic and intense assault therapy of hereditary angioedema.

Latest Trends:

The following are the trending factors encouraging the Plasma protease C1-Inhibitor treatment market growth over the coming years:

  • Growing incidence of hereditary angioedema (HAE).
  • Biopharmaceutical companies focusing on the development of effective plasma protease C1-inhibitor.
  • Adoption of inorganic development techniques.
  • Selective Bradykinin B2 Receptor Antagonist Segment is expected to increase the market.
  • Increased product approvals.

Driving Factors:

  • Factors such as the revelation of inhibitor drugs, expanding R&D investments, expanding item endorsements promising pipeline medications, and novel treatments for the treatment of hereditary angioedema are a couple of different elements driving the plasma protease c1 inhibitor treatment market.
  • Hereditary angioedema is a conceivably hazardous hereditary condition. Incidences of hereditary angioedema (HAE) increasing day by day. The growing incidence of hereditary angioedema (HAE) is the major factor in boosting the protease c1 inhibitor treatment market.
  • Biopharmaceutical companies focusing on developing effective plasma protease C1-inhibitor treatment drugs/therapies for treating various health conditions such as diabetic macular edema (DME), HAE, and others, are propelling the plasma protease C1-inhibitor treatment market.
  • Adoption of inorganic development techniques, for example, organizations and coordinated efforts, to create innovative protease C1-inhibitor treatment is fundamentally adding to the development of the global plasma protease C1-inhibitor treatment market.

Restraining Factors:

  • The less occurrence of the HAE makes it hard for the productive conclusion and picking alternative treatments to control the infection is the central point that is relied upon to limit the plasma protease c1-inhibitor treatment market development.
  • The spread of the novel coronavirus has hampered the growth of the healthcare industry and the virus has spread rapidly across the globe. Various research institutes and biopharmaceutical companies are engaged in the study of the effects of plasma protease C1-inhibitors in treating significant systemic abnormalities in patients with COVID‐ This factor hampers the growth of the C1-inhibitors market.

Segmentations:

The global Plasma protease C1-Inhibitor treatment market has been bifurcated into different global market segments by examining various perspectives such as drug type, dosage, distribution channel, and global geographies. Based on drug type, it can be divided into C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist. Based on dosage, it can be divided into Lyophilized and Injectable. Based on the distribution channel, it can be divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Drug Type Perspective (Revenue in US$ Million):

  • C1-inhibitors
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist

Dosage Perspective (Revenue in US$ Million):

  • Lyophilized
  • Injectable

Distribution Channel Perspective (Revenue in US$ Million):

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Perspective (Revenue in US$ Million):

North America

  • U.S.A
  • Canada

Europe

  • Italy
  • Germany
  • France
  • UK
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico

Middle East & Africa

  • UAE
  • Saudi Arabia
  • Turkey
  • Rest of Middle East & Africa

Regional Insights:

  • The global Plasma protease C1-Inhibitor treatment market has been scrutinized into different global market regions such as North America, Asia-Pacific, Africa, and Europe, Latin America, and the Middle East based on different global market segments.
  • North American plasma protease C1-inhibitor treatment market is expected to exhibit significant growth during the forecast period, inferable from expanding endorsements of novel treatments by the administrative offices, for example, the U.S. Food and Drug Administration. For example, in 2014, the U.S. FDA affirmed Pharming Healthcare’s Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.
  • In North America, rising Hereditary Angioedema (HAE) and expanding R&D ventures. Different factors additionally incorporate the presence of entrenched medical care framework, an expanding number of item endorsements, and significant market players giving successful therapy choices to the patients experiencing Hereditary Angioedema in North America. These factors increase the demand for the Plasma Protease C1-inhibitor market.

Key Industry Players:

Different global established global companies in the global Plasma protease C1-Inhibitor treatment market have been examined with the help of research methodologies for getting effective insights based on various perspectives. Furthermore, different factors such as collaborations, mergers, and acquisitions, partnerships of leading competitors have been presented in the report. Furthermore, a different financial factor such as financial overview, profit margin, revenue generation, and investments have been estimated by an expert team of Alchemy Market Research.

The following leading companies have been profiled to get detailed insights into leading companies in the Plasma protease C1-Inhibitor treatment market:

  • CSL Behring LLC
  • Takeda Pharmaceutical Company Limited
  • BioCryst Pharmaceuticals
  • Pharming Technologies B.V
  • Centogene AG
  • KalVista Pharmaceuticals, Inc
  • Ionis Pharmaceuticals, Inc

Key Industry Developments:

  • In October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 for the development of potential treatment of diabetic macular edema (DME).

This report answers the following key questions:

  • What is the global Plasma protease C1-Inhibitor treatment market?
  • Which factors are encouraging and driving the global Plasma protease C1-Inhibitor treatment market?
  • What are the upcoming trends and evolution of the Plasma protease C1-Inhibitor treatment market?
  • What are the challenges, threats, and issues faced by the global Plasma protease C1-Inhibitor treatment market?
  • What will be the global market size and market shares over the forecast period?
  • What are the global leading key players functioning in the global Plasma protease C1-Inhibitor treatment market?
  • What are the outcomes of SWOT and Porter’s five forces analysis?
  • What are the technological advancements and trends in the global Plasma protease C1-Inhibitor treatment market?
  • What is the impact of the Covid-19 viral outbreak on the global Plasma protease C1-Inhibitor treatment market?
  • What will be the global Plasma protease C1-Inhibitor treatment market growth opportunities over the forecast period?
  • Which are the major segments accounted for registering the largest share in the global Plasma protease C1-Inhibitor treatment market?
Report Synopsis

Synopsis:

Alchemy Market Research has newly published a fully-fledged analysis on the global Plasma protease C1-Inhibitor treatment market to its large volume of database. The global Plasma protease C1-Inhibitor treatment market size is accounted to hold at US$ 3290 million in 2020 and is projected to register a CAGR of 18.2 % over the forecast period. The global market data has been collected through a blend of research techniques such as primary and secondary research. Furthermore, an expert team of Alchemy Market Research makes use of qualitative and quantitative analysis. The business intelligence report highlights the recent updates of the global market along with its statistics for a better understanding of the present scenario of the market.

Table of Content

Chapter 1.        Executive Summary

 

Chapter 2.        Market Introduction

 

Chapter 3.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics

3.1.   Key Market Drivers

3.2.   Key Market Restraints

3.3.   Market Opportunities

3.4.   Future Trends

3.5.   Impact Analysis of Drivers and Restraints

Chapter 4.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

 

Chapter 5.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Drug Type

5.1.   C1-inhibitors

5.2.   Kallikrein Inhibitor

5.3.   Selective Bradykinin B2 Receptor Antagonist

Chapter 6.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Dosage

6.1.   Lyophilized

6.2.   Injectable

Chapter 7.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Distribution Channel

7.1.   Hospital Pharmacies

7.2.   Retail Pharmacies

7.3.   Online Pharmacies

Chapter 8.        Global Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028 – By Region

8.1.   North America

8.2.   Europe

8.3.   Asia-Pacific

8.4.   Latin America

8.5.   Middle East & Africa

Chapter 9.        North America Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

9.1.   North America Plasma Protease C1- inhibitor treatment Market– By Drug Type

9.1.1.C1-inhibitors

9.1.2.Kallikrein Inhibitor

9.1.3.Selective Bradykinin B2 Receptor Antagonist

9.2.   North America Plasma Protease C1- inhibitor treatment Market– By Dosage

9.2.1.Lyophilized

9.2.2.Injectable

9.3.   North America Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

9.3.1.Hospital Pharmacies

9.3.2.Retail Pharmacies

9.3.3.Online Pharmacies

9.4.   North America Plasma Protease C1- inhibitor treatment Market– By Country

9.4.1.U.S.

9.4.2.Canada

Chapter 10.    Europe Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

10.1.            Europe Plasma Protease C1- inhibitor treatment Market– By Drug Type

10.1.1.    C1-inhibitors

10.1.2.    Kallikrein Inhibitor

10.1.3.    Selective Bradykinin B2 Receptor Antagonist

10.2.            Europe Plasma Protease C1- inhibitor treatment Market– By Dosage

10.2.1.    Lyophilized

10.2.2.    Injectable

10.3.            Europe Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

10.3.1.    Hospital Pharmacies

10.3.2.    Retail Pharmacies

10.3.3.    Online Pharmacies

10.4.            Europe Plasma Protease C1- inhibitor treatment Market– By Country

10.4.1.    Germany

10.4.2.    France

10.4.3.    UK

10.4.4.    Spain

10.4.5.    Italy

10.4.6.    Rest of Europe

Chapter 11.    Asia Pacific Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

11.1.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Drug Type

11.1.1.    C1-inhibitors

11.1.2.    Kallikrein Inhibitor

11.1.3.    Selective Bradykinin B2 Receptor Antagonist

11.2.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Dosage

11.2.1.    Lyophilized

11.2.2.    Injectable

11.3.            Asia Pacific Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

11.3.1.    Hospital Pharmacies

11.3.2.    Retail Pharmacies

11.3.3.    Online Pharmacies

11.4.            Asia-Pacific Plasma Protease C1- inhibitor treatment Market– By Country

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. South Korea

11.4.5. Rest of Asia-Pacific

Chapter 12.    Latin America Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

12.1.            Latin America Plasma Protease C1- inhibitor treatment Market– By Drug Type

12.1.1.    C1-inhibitors

12.1.2.    Kallikrein Inhibitor

12.1.3.    Selective Bradykinin B2 Receptor Antagonist

12.2.            Latin America Plasma Protease C1- inhibitor treatment Market– By Dosage

12.2.1.    Lyophilized

12.2.2.    Injectable

12.3.            Latin America Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

12.3.1.    Hospital Pharmacies

12.3.2.    Retail Pharmacies

12.3.3.    Online Pharmacies

12.4.            Latin America Plasma Protease C1- inhibitor treatment Market– By Country

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

Chapter 13.    Middle East & Africa Plasma Protease C1- inhibitor treatment Market– Analysis and Revenue Forecast 2019-2028

13.1.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Drug Type

13.1.1.    C1-inhibitors

13.1.2.    Kallikrein Inhibitor

13.1.3.    Selective Bradykinin B2 Receptor Antagonist

13.2.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Dosage

13.2.1.    Lyophilized

13.2.2.    Injectable

13.3.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Distribution Channel

13.3.1.    Hospital Pharmacies

13.3.2.    Retail Pharmacies

13.3.3.    Online Pharmacies

13.4.            Middle East & Africa Plasma Protease C1- inhibitor treatment Market– By Country

13.4.1. UAE

13.4.2. Saudi Arabia

13.4.3. Turkey

13.4.4. Rest of Middle East & Africa

Chapter 14.    Competitive Analysis

14.1.1. Competition Dashboard

14.1.2. Company Profiles

14.1.2.1.          CSL Behring LLC

14.1.2.2.          Takeda Pharmaceutical Company Limited

14.1.2.3.          BioCryst Pharmaceuticals

14.1.2.4.          Pharming Technologies B.V

14.1.2.5.          Centogene AG

14.1.2.6.          KalVista Pharmaceuticals, Inc

Ionis Pharmaceuticals, Inc

Report Sample
Report Methodology
Report Customization
Consult the Analyst